Furthermore, multiple studies have shown that plasma PAI-1 activity and the formation of tPA/PAI-1 complexes were significantly reduced in APL patients via a proposed mechanism involving proteolytic degradation of PAI-1, leading to an inability to counteract APL-driven tPA hyperactivity [41,48]. This evidence concerns the gene PLAT and acute promyelocytic leukemia.